The Effects of Fasciola Hepatica Recombinant Proteins (Peroxiredoxin and Cathepsin L1) on Crohn's Disease Experimental Model Publisher Pubmed



Hasanpour H^{1, 2} ; Falak R^{3, 4} ; Mokhtarian K⁵ ; Sadeghi F⁶ ; Masoumi E^{7, 8} ; Asadollahi P⁹ ; Badirzadeh A¹⁰ ; Azami SJ¹¹ ; Gholami MD⁴ ; Pashangzadeh S⁴ ; Gharagozlou MJ¹² ; Naserifar R^{1, 2} ; Mowlavi G¹¹ Show Affiliations
Source: Parasite Immunology Published:2024

Abstract

The immunomodulatory potential of the excretory-secretory (E/S) proteins of the helminths has been shown in previous investigations. This study evaluated the effects of the recombinants and excretory-secretory proteins of the Fasciola hepatica on induced colitis in Balb/c mice. The F. hepatica Recombinant proteins, Cathepsin L1 and Peroxiredoxin, and E/S proteins were intraperitoneally injected into the three mice groups as the case groups, while the control groups received PBS. Colitis was induced in mice by intraluminal administration of the 2, 4, 6-Trinitrobenzenesulfonic acid solution (TNBS). After 8 h, the case groups received the second dosage of the treatments, and it was repeated 24 h later. The immunological, pathological, and macroscopic changes were evaluated 3 days after colitis induction. The macroscopic evaluation revealed significantly lower inflammatory scores in the mice treated with recombinant Peroxiredoxin (rPRX) and recombinant Cathepsin L1 (rCL1). Despite the macroscopic observation, the pathological finding was insignificant between the groups. IFN-γ secretion was significantly lower in splenocytes of the groups that received rPRX, rCL1, and E/S than the controls. IL-10 showed significantly higher levels in groups treated with rPRX and rCL1 than controls, whereas the level of IL-4 was not statistically significant. Excretory-secretory proteins of the F. hepatica showed immunomodulatory potency and the main effects observed in this study were through the reduction of inflammatory cytokine and inflammation manifestation as well as induction of anti-inflammatory cytokines. © 2024 John Wiley & Sons Ltd.